全文获取类型
收费全文 | 5906篇 |
免费 | 60篇 |
国内免费 | 63篇 |
专业分类
耳鼻咽喉 | 23篇 |
儿科学 | 733篇 |
妇产科学 | 207篇 |
基础医学 | 533篇 |
口腔科学 | 248篇 |
临床医学 | 178篇 |
内科学 | 1228篇 |
皮肤病学 | 274篇 |
神经病学 | 158篇 |
特种医学 | 115篇 |
外国民族医学 | 2篇 |
外科学 | 1147篇 |
综合类 | 258篇 |
预防医学 | 117篇 |
眼科学 | 95篇 |
药学 | 294篇 |
中国医学 | 163篇 |
肿瘤学 | 256篇 |
出版年
2023年 | 5篇 |
2022年 | 10篇 |
2021年 | 86篇 |
2020年 | 17篇 |
2019年 | 658篇 |
2018年 | 530篇 |
2017年 | 307篇 |
2016年 | 21篇 |
2015年 | 22篇 |
2014年 | 63篇 |
2013年 | 58篇 |
2012年 | 62篇 |
2011年 | 67篇 |
2010年 | 53篇 |
2009年 | 72篇 |
2008年 | 103篇 |
2007年 | 108篇 |
2006年 | 56篇 |
2005年 | 84篇 |
2004年 | 43篇 |
2003年 | 42篇 |
2002年 | 45篇 |
2001年 | 43篇 |
2000年 | 27篇 |
1999年 | 29篇 |
1998年 | 23篇 |
1997年 | 24篇 |
1996年 | 25篇 |
1995年 | 9篇 |
1994年 | 19篇 |
1993年 | 15篇 |
1992年 | 17篇 |
1991年 | 16篇 |
1990年 | 7篇 |
1989年 | 9篇 |
1988年 | 11篇 |
1986年 | 7篇 |
1985年 | 269篇 |
1984年 | 355篇 |
1983年 | 210篇 |
1982年 | 288篇 |
1981年 | 273篇 |
1980年 | 252篇 |
1979年 | 286篇 |
1978年 | 223篇 |
1977年 | 215篇 |
1976年 | 254篇 |
1975年 | 209篇 |
1974年 | 188篇 |
1973年 | 205篇 |
排序方式: 共有6029条查询结果,搜索用时 10 毫秒
21.
目的探讨调营饮对小鼠S180肝癌腹水模型腹膜淋巴孔的影响。方法取S180细胞接种于小鼠腹腔造成肝癌腹水模型,随机分为空白对照组(NS)、模型组(M)、调营饮低剂量组(TA)、调营饮高剂量组(TB)、模型+NO供组(NO)、调营饮高剂量组+NOS抑制剂组(NOS),造模后第5d用调营饮连续灌胃,观察对小鼠腹膜淋巴孔的影响。结果 TA组和TB组腹膜淋巴孔的平均周长、平均面积和平均密度均明显大于NS组和M组(P〈0.01),NO组腹膜淋巴孔平均周长、平均面积和平均密度明显大于相对应的M组(P〈0.01),NOS组的腹膜淋巴孔平均周长、平均面积和平均密度明显少于相对应的TB组(P〈0.01),TA与TB组比较差异无统计学意义(P〉0.05)。结论调营饮对小鼠S180肝癌腹水模型有明显促进腹膜淋巴孔开放面积增大、周长和分布密度增加的作用,可能是其消腹水作用机制之一。 相似文献
22.
本文报道了中药雷丸注射液抗小白鼠S_(180)后瘤块的组织学观察。肉眼观察治疗组小鼠的瘤块明显变小;瘤块重量明显减轻,计算其肿瘤生长抑制率为85.2~88%,对照组与治疗组之间有高度显著性差异(P<0.01)。瘤决H.E染色连续切片的光镜观察,有的看不到S_(180)细胞,全部为白细胞巨噬细胞及多核巨细胞浸润,有的只见少量残余的S_(180)细胞小团或小索由大量的上述细胞浸润所包围。此外,可见上述细胞一系列退变解体的组织学改变,瘤块周围的结缔组织及毛细血管向其内增生,并见大量淋巴细胞浸润。 相似文献
23.
24.
25.
Kevin Hodges Carlos Godoy Rivas José Aguilera Robert Borden Alaa Alashi Eugene H. Blackstone Milind Y. Desai Nicholas G. Smedira 《The Journal of thoracic and cardiovascular surgery》2019,157(6):2289-2299
ObjectivesThis study evaluates operative approach and contemporary surgical outcomes in the management of left ventricular outflow tract obstruction by a single surgeon at a high-volume, specialized hypertrophic cardiomyopathy center.MethodsThis is a retrospective review of 1559 consecutive operations for left ventricular outflow tract obstruction from 2005 to 2015. Demographic profiles, echocardiogram-derived ventricular morphology and hemodynamics, operative data, and in-hospital outcomes were analyzed.ResultsOf the 1559 operations, 586 were isolated septal myectomies, 522 were myectomies with mitral valve or subvalvular apparatus intervention, 422 were myectomies with another concomitant procedure, and 29 were isolated mitral valve interventions without myectomy. Common mitral valve interventions included anterior leaflet shortening (16%), chordae tendineae resection (9.8%), papillary muscle resection (7.2%), and papillary muscle reorientation (7.5%). Ninety-two patients underwent mitral valve replacement, 42 for left ventricular outflow tract obstruction and 50 for intrinsic mitral valve pathology. Patients undergoing mitral interventions had thinner septums (18 ± 0.4 mm vs 22 ± 0.5 mm, P < .001) and less myocardium removed (6.2 ± 3.5 g vs 8.8 ± 3.8 g, P < .001) than patients without a mitral intervention. Prevalence of in-hospital permanent pacemaker insertion was 4.2% (n = 1334) for complete heart block and 1.1% (n = 464) for isolated septal myectomy with normal preoperative conduction. Overall, there were 2 postoperative ventricular septal defects (0.13%) and none for isolated myectomies. Operative mortality was 0.38%.ConclusionsSeptal myectomy can be performed safely with excellent outcomes when the procedure is performed by a highly experienced surgeon in a high-volume, specialized center. A mitral valve intervention is a useful adjunct in patients with moderate hypertrophy. 相似文献
26.
27.
Rabbit pancreatic islet cytosol catalyzes the calcium-activated phosphorylation by [gamma 32P]ATP of a protein with a molecular weight of 57,000 that is precipitated with antipyruvate kinase antibodies. We were unable to demonstrate that phosphorylation in the presence of calcium or cAMP had any immediate effect on rat pancreatic islet pyruvate kinase activity. This finding is consistent with our inability to confirm the finding of others that pancreatic islets contain phosphoenolpyruvate carboxykinase activity (Diabetes, 34:246, 1985). Since the carboxykinase catalyzes phosphoenolpyruvate formation and pyruvate kinase catalyzes essentially the opposite reaction, if the carboxykinase were present in the beta cell, pyruvate kinase would need to be inhibited to prevent recycling of phosphoenolpyruvate. 相似文献
28.
Jocelyn M. Beach Yuki Kuramochi Corey Brier Eric E. Roselli Matthew J. Eagleton 《Journal of vascular surgery》2017,65(5):1287-1296
Objective
Long-term data regarding the safety and durability of thoracic endovascular aortic repair (TEVAR) are limited. The study objective was to evaluate the long-term outcomes of TEVAR in high-risk patients with descending thoracic aortic pathology.Methods
High-risk patients were treated with thoracic endografts (2001-2011) under a prospective, physician-sponsored, investigational device exemption trial. Three-dimensional reconstructions and measurements were performed on computed tomography scans acquired before discharge, at 1, 6, and 12 months, and then yearly thereafter.Results
The study included 200 patients, of whom 171 were treated for thoracic aneurysm, 28 for chronic dissection, and 1 for aortobronchial fistula. Patients were monitored for an average of 4.8 ± 3.3 years, and 93 (46.5%) were monitored for >5 years. Operative mortality was 6.5%. Survival at 30 days and at 1, 5, and 9 years was 94.0%, 85.8%, 55.6%, and 31.4%, and freedom from aneurysm-related death was 94.0%, 92.4%, 91.7%, 91.7%, respectively. Sixty-one endoleaks occurred in 54 patients (28%). Sixty-seven reinterventions were performed in 50 patients. Overall freedom from reintervention at 30 days, 1, 5, and 9 years was 87.9%, 82.9%, 75.5%, and 64.0%, respectively. Forty-seven reinterventions (70%) were thoracic aneurysm-related, 35 (74%) of which were endovascular procedures. Thirty of these were to correct endoleaks at a median of 1.4 years (interquartile range, 0.2-5.0 years).Conclusions
TEVAR is durable and associated with high long-term aneurysm-related survival. Long-term imaging follow-up remains critical to identify endoleaks or rare device durability issues, most of which can be monitored or managed with endovascular therapies. 相似文献29.
30.
胡桃楸提取物对S180肉瘤的抑制作用及机制 总被引:5,自引:0,他引:5
目的:研究胡桃楸提取物(JMME)对小鼠S180肉瘤的抑制作用及其免疫调节用。方法:对 3组荷瘤鼠(每组10只)用0.023、0.045和0.090 g•kg-1•d-1
JMME灌胃给药,同时设阴性对照组和阳性对照组,检测JMME对小鼠体内移植性肿瘤S180肉瘤的抑瘤率;以细胞培养观察JMME对S180细胞生长的抑制作用; MTT法观察JMME对肿瘤坏死因子(TNF)活性和白细胞介素2(IL-2)诱生水平的影响。结果:JMME具有明显的抑制肿瘤的作用,不同浓度的抑瘤率分别为32%、43%和56%
,与阴性对照组比较差异有显著性(P<0.05);对体外培养的肿瘤细胞增殖抑制率可高达60.10%,与对照组比较差异有显著性(P<0.05);TNF活性及IL-2诱生水平较对照组明显增高(P<0.05); 。结论: JMME具有显著抑制肿瘤的作用,其抑瘤作用机制是抑制肿瘤细胞的增殖并调节机体的免疫功能。 相似文献